These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Risperidone and clozapine for treatment-resistant schizophrenia. Meltzer HY Am J Psychiatry; 1999 Jul; 156(7):1126-7; author reply 1127-8. PubMed ID: 10401484 [No Abstract] [Full Text] [Related]
5. The CATIE study. Basil B; Mathews M; Adetunji B; Budur K Am J Psychiatry; 2006 Mar; 163(3):555; author reply 555-6. PubMed ID: 16513895 [No Abstract] [Full Text] [Related]
6. Clinical trials design lessons from the CATIE study. Kraemer HC; Glick ID; Klein DF Am J Psychiatry; 2009 Nov; 166(11):1222-8. PubMed ID: 19797435 [TBL] [Abstract][Full Text] [Related]
7. Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent doses. Tandon R; Nasrallah HA Arch Gen Psychiatry; 2006 Aug; 63(8):935-7; author reply 937-9. PubMed ID: 16894070 [No Abstract] [Full Text] [Related]
8. First- vs second-generation antipsychotic drugs in schizophrenia. Andrade C; Kharawala S Arch Gen Psychiatry; 2007 Aug; 64(8):978-9; author reply 979-80. PubMed ID: 17679643 [No Abstract] [Full Text] [Related]
9. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Lieberman JA Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808 [No Abstract] [Full Text] [Related]
11. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Heinrichs RW Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745 [No Abstract] [Full Text] [Related]
12. Comparative effectiveness of antipsychotic drugs. Osser DN; Akhter A Am J Psychiatry; 2003 Mar; 160(3):590; author reply 592-3. PubMed ID: 12611853 [No Abstract] [Full Text] [Related]
13. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Woods SW; Gueorguieva RV; Baker CB; Makuch RW Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728 [TBL] [Abstract][Full Text] [Related]
14. First- and second-generation antipsychotics: learning from CUtLASS and CATIE. Tandon R; Carpenter WT; Davis JM Arch Gen Psychiatry; 2007 Aug; 64(8):977-8; author reply 979-80. PubMed ID: 17679642 [No Abstract] [Full Text] [Related]
15. The costs of drugs for schizophrenia. Freedman R; Carpenter WT; Davis JM; Goldman HH; Tamminga CA; Thomas M Am J Psychiatry; 2006 Dec; 163(12):2029-31. PubMed ID: 17151146 [No Abstract] [Full Text] [Related]
16. [Priority for atypical antipsychotic drugs? Current studies clarify the issues]. Dose M Psychiatr Prax; 2007 Jan; 34(1):46-9. PubMed ID: 17265252 [No Abstract] [Full Text] [Related]